These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 24837642)
21. Hypersexuality and paraphilia induced by selegiline in Parkinson's disease: report of 2 cases. Shapiro MA; Chang YL; Munson SK; Okun MS; Fernandez HH Parkinsonism Relat Disord; 2006 Sep; 12(6):392-5. PubMed ID: 16730214 [TBL] [Abstract][Full Text] [Related]
22. Evaluation of the safety and tolerability of rasagiline in the treatment of the early stages of Parkinson's disease. Viallet F; Pitel S; Lancrenon S; Blin O Curr Med Res Opin; 2013 Jan; 29(1):23-31. PubMed ID: 23176073 [TBL] [Abstract][Full Text] [Related]
23. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Chen JJ; Swope DM; Dashtipour K Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186 [TBL] [Abstract][Full Text] [Related]
24. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E; Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996 [TBL] [Abstract][Full Text] [Related]
25. Long-term efficacy of rasagiline in early Parkinson's disease. Lew MF; Hauser RA; Hurtig HI; Ondo WG; Wojcieszek J; Goren T; Fitzer-Attas CJ Int J Neurosci; 2010 Jun; 120(6):404-8. PubMed ID: 20504210 [TBL] [Abstract][Full Text] [Related]
26. Rasagiline for motor complications in Parkinson's disease. Clarke CE Lancet; 2005 Mar 12-18; 365(9463):914-6. PubMed ID: 15766976 [No Abstract] [Full Text] [Related]
27. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease. Guay DR Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539 [TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson's disease. Müller T Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1423-32. PubMed ID: 25196265 [TBL] [Abstract][Full Text] [Related]
29. Drug-Associated Spontaneous Orgasm: A Case Report and Systematic Review of Literature. Chen WH; Chu YH; Chen KY Clin Neuropharmacol; 2018; 41(1):31-37. PubMed ID: 29194112 [TBL] [Abstract][Full Text] [Related]
30. MAO-B inhibitor know-how: back to the pharm. Lewitt PA Neurology; 2009 Apr; 72(15):1352-7. PubMed ID: 19365057 [No Abstract] [Full Text] [Related]
31. [Rasagiline in monotherapy in patients with early stages of Parkinson's disease and in combined and adjunct therapy to levodopa with moderate and advanced stages]. Pagonabarraga J; Rodríguez-Oroz MC Rev Neurol; 2013 Jan; 56(1):25-34. PubMed ID: 23250679 [TBL] [Abstract][Full Text] [Related]
32. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Parkinson Study Group Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852 [TBL] [Abstract][Full Text] [Related]
34. Rasagiline effect on bladder disturbances in early mild Parkinson's disease patients. Brusa L; Musco S; Bernardi G; Iani C; Pierantozzi M; Stanzione P; Stefani A; Finazzi Agro' E Parkinsonism Relat Disord; 2014 Aug; 20(8):931-2. PubMed ID: 24861661 [No Abstract] [Full Text] [Related]
35. Bupropion-SR-induced increased libido and spontaneous orgasm. Labbate LA Can J Psychiatry; 1998 Aug; 43(6):644-5. PubMed ID: 9729695 [No Abstract] [Full Text] [Related]
36. Three cases of impulse control disorder in Parkinson's disease patients receiving dopamine replacement therapy. Wilson L; Sheehan J; Thorpe M Ir Med J; 2013 Jan; 106(1):24-5. PubMed ID: 23472375 [TBL] [Abstract][Full Text] [Related]